Berkshire Hathaway’s Royalty Pharma RPRX Stock Holding History

Berkshire Hathaway’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,496,372	Closed	-$58.3M	–	48
2022 Q1	$58.3M	Sell	1,496,372 -7,151,896	-83%	-$281M	0.02%	41
2021 Q4	$345M	Sell	8,648,268 -4,497,634	-34%	-$175M	0.1%	30
2021 Q3	$475M	Buy	+13,145,902	New	+$511M	0.16%	29

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Berkshire Hathaway's RPRX Position: Q2 2022 in Review

Berkshire Hathaway sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 1,496,372 shares — an estimated $58.3M sold.

Berkshire Hathaway first reported a position in RPRX in Q3 2021 and held it in 3 quarters. The position peaked at $475M in Q3 2021. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

Berkshire Hathaway reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
Berkshire Hathaway sold 1,496,372 Royalty Pharma shares in Q2 2022, an estimated $58.3M.
Berkshire Hathaway first reported a position in Royalty Pharma in Q3 2021 and held it in 3 quarters.
Berkshire Hathaway's Royalty Pharma position peaked at $475M in Q3 2021.
283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on Berkshire Hathaway's 13F filing for Q2 2022, filed 15 Aug 2022.